Abstract

Research Article

Pharmaceutical and Biopharmaceutical Industries: Revolutionizing Healthcare

Rehan Haider*

Published: 27 December, 2023 | Volume 7 - Issue 1 | Pages: 083-089

The drug and biopharmaceutical enterprises play a pivotal part in transforming healthcare through the incident and delivery of creative cures and remedies. This item explores the key facets of these areas, stressing their impact on healthcare.
Pharmaceuticals, outlined as wealthy secondhand in the diagnosis, situation, or stop of disease, aim to restore, correct, or refine everyday functions. On the other hand, biopharmaceuticals (or biologicals) circumscribe sugars, proteins, nucleic acids, living containers, or tissues and are curative devices that arise natural beginnings to a degree persons, animals, or microorganisms. In contrast to common pills combined with synthetic processes, biopharmaceuticals are primarily acquired through unaffected processes, containing extraction from living constructions or production utilizing alteration of genetic material Table 1.
•    Some usual biopharmaceuticals, originally gleaned from animals or persons, are immediately created through biotechnological advancements.
•    For instance, healing insulin, previously gleaned from porcine pancreatic islets, is immediately made utilizing alteration of genetic material in yeast (Saccharomyces cerevisiae) or E. coli.
•    Biopharmaceuticals caused by alteration of genetic material usually fall into three classifications:
•    Substances nearly equal to the body’s own key signaling proteins.
•    Monoclonal antibodies look like those caused by apiece human immune plan against bacteria.
•    Receptor builds (fusion proteins) established uniformly happening receptors connected to the immunoglobulin frame.
Examples include
From living systems: Whole blood and ancestry parts, organs and fabric transplants, stem containers, antibodies for inactive immunization, polluted microbiota, human bosom milk, and human reproductive containers.
Produced by recombinant DNA: Blood determinants, fabric plasminogen activators, hormones, hematopoietic growth determinants, interferon, interleukin-located produce, vaccines, monoclonal antibodies, tumor loss determinants, therapeutic enzymes.
•    Key dispute Pharmaceutical manufacturing
•    Biopharmaceuticals
•    Healthcare strike
•    Innovative medicines
•    Therapeutic fragments
•    Recombinant DNA technologies
•    Personalized cure
•    Gene medicines
•    Regulatory processes.

Read Full Article HTML DOI: 10.29328/journal.apps.1001047 Cite this Article Read Full Article PDF

References

  1. Chen YC, Cheng HF, Yeh MK. Cell Therapy Regulation in Taiwan. Cell Transplant. 2017 Mar 13;26(3):483-492. doi: 10.3727/096368916X693293. Epub 2016 Sep 30. PMID: 27697103; PMCID: PMC5657697.
  2. Gonçalves GAR, Paiva RMA. Gene therapy: advances, challenges and perspectives. Einstein (Sao Paulo). 2017 Jul-Sep;15(3):369-375. doi: 10.1590/S1679-45082017RB4024. PMID: 29091160; PMCID: PMC5823056.
  3. Marei MK, El Backly RM. Dental Mesenchymal Stem Cell-Based Translational Regenerative Dentistry: From Artificial to Biological Replacement. Front Bioeng Biotechnol. 2018 May 2;6:49. doi: 10.3389/fbioe.2018.00049. PMID: 29770323; PMCID: PMC5941981.
  4. Shoji T, Shinoka T. Tissue engineered vascular grafts for pediatric cardiac surgery. Transl Pediatr. 2018 Apr;7(2):188-195. doi: 10.21037/tp.2018.02.01. PMID: 29770300; PMCID: PMC5938251.
  5. Stephenson M, Grayson W. Recent advances in bioreactors for cell-based therapies. F1000Res. 2018 Apr 30;7:F1000 Faculty Rev-517. doi: 10.12688/f1000research.12533.1. PMID: 29770207; PMCID: PMC5931275.
  6. Nick C. The US Biosimilars Act: Challenges handling supervisory authorization. Pharmaceutical Medicine. 2012; 26 (3):145-152. DOI: 10.1007/bf03262388.
  7. Camacho LH, Frost CP, Abella E, Morrow PK, Whittaker S. Biosimilars 101: considerations for U.S. oncologists in clinical practice. Cancer Med. 2014 Aug;3(4):889-99. doi: 10.1002/cam4.258. Epub 2014 May 9. PMID: 24810680; PMCID: PMC4303156.
  8. Lamanna WC, Holzmann J, Cohen HP, Guo X, Schweigler M, Stangler T, Seidl A, Schiestl M. Maintaining consistent quality and clinical performance of biopharmaceuticals. Expert Opin Biol Ther. 2018 Apr;18(4):369-379. doi: 10.1080/14712598.2018.1421169. Epub 2018 Jan 10. PMID: 29285958.
  9. Strati P, Jain N, O'Brien S. Chronic Lymphocytic Leukemia: Diagnosis and Treatment. Mayo Clin Proc. 2018 May;93(5):651-664. doi: 10.1016/j.mayocp.2018.03.002. PMID: 29728204.
  10. Marr KA, Datta K, Mehta S, Ostrander DB, Rock M, Francis J, Feldmesser M. Urine Antigen Detection as an Aid to Diagnose Invasive Aspergillosis. Clin Infect Dis. 2018 Nov 13;67(11):1705-1711. doi: 10.1093/cid/ciy326. PMID: 29684106; PMCID: PMC6233688.
  11. Phuong NH, Kwak C, Heo CK, Cho EW, Yang J, Poo H. Development and Characterization of Monoclonal Antibodies against Nucleoprotein for Diagnosis of Influenza A Virus. J Microbiol Biotechnol. 2018 May 28;28(5):809-815. doi: 10.4014/jmb.1801.01002. PMID: 29642295.
  12. Chen YC, Cheng HF, Yang YC, Yeh MK. Nanotechnologies secondhand in biomedical vaccines. In: Stanciu SG, redactor. Micro and Nanotechnologies for Biotechnology. Rijeka, Croatia: InTech; 2016; 85-105. DOI: 10.5772/63453.
  13. Chen YC, Cheng HF, Yang YC, Yeh MK. Biotechnologies secondhand in biomedical vaccines. In: Afrin F, Hemeg H, Ozbak H, editors. Vaccine. Rijeka, Croatia: InTech; 2017; 97-110. DOI: 10.5772/intechopen.69547.
  14. Das SK, Menezes ME, Bhatia S, Wang XY, Emdad L, Sarkar D, Fisher PB. Gene Therapies for Cancer: Strategies, Challenges and Successes. J Cell Physiol. 2015 Feb;230(2):259-71. doi: 10.1002/jcp.24791. PMID: 25196387; PMCID: PMC4363073.
  15. Bai Y, Gong H, Li H, Vu GP, Lu S, Liu F. Oral delivery of RNase P ribozymes by Salmonella inhibits viral infection in mice. Proc Natl Acad Sci U S A. 2011 Feb 22;108(8):3222-7. doi: 10.1073/pnas.1014975108. Epub 2011 Feb 7. PMID: 21300908; PMCID: PMC3044408.
  16. Gan WB, Grutzendler J, Wong WT, Wong RO, Lichtman JW. Multicolor "DiOlistic" labeling of the nervous system using lipophilic dye combinations. Neuron. 2000 Aug;27(2):219-25. doi: 10.1016/s0896-6273(00)00031-3. PMID: 10985343.
  17. Guo W, Guo Y, Tang S, Qu H, Zhao H. Dendritic cell-Ewing's sarcoma cell hybrids enhance antitumor immunity. Clin Orthop Relat Res. 2008 Sep;466(9):2176-83. doi: 10.1007/s11999-008-0348-7. Epub 2008 Jun 19. PMID: 18563501; PMCID: PMC2493000.
  18. Stewart MP, Sharei A, Ding X, Sahay G, Langer R, Jensen KF. In vitro and ex vivo strategies for intracellular delivery. Nature. 2016 Oct 13;538(7624):183-192. doi: 10.1038/nature19764. PMID: 27734871.
  19. Oggu GS, Sasikumar S, Reddy N, Ella KKR, Rao CM, Bokara KK. Gene Delivery Approaches for Mesenchymal Stem Cell Therapy: Strategies to Increase Efficiency and Specificity. Stem Cell Rev Rep. 2017 Dec;13(6):725-740. doi: 10.1007/s12015-017-9760-2. PMID: 28815481.
  20. Xiao Q, Min T, Ma S, Hu L, Chen H, Lu D. Intracellular generation of single-strand template increases the knock-in efficiency by combining CRISPR/Cas9 with AAV. Mol Genet Genomics. 2018 Aug;293(4):1051-1060. doi: 10.1007/s00438-018-1437-2. Epub 2018 Apr 18. PMID: 29671068.
  21. Finn JD, Smith AR, Patel MC, Shaw L, Youniss MR, van Heteren J, Dirstine T, Ciullo C, Lescarbeau R, Seitzer J, Shah RR, Shah A, Ling D, Growe J, Pink M, Rohde E, Wood KM, Salomon WE, Harrington WF, Dombrowski C, Strapps WR, Chang Y, Morrissey DV. A Single Administration of CRISPR/Cas9 Lipid Nanoparticles Achieves Robust and Persistent In Vivo Genome Editing. Cell Rep. 2018 Feb 27;22(9):2227-2235. doi: 10.1016/j.celrep.2018.02.014. PMID: 29490262.
  22. Lau CH, Suh Y. In vivogenome editing in animals using AAV-CRISPR system: applications to translational research of human disease. F1000Res. 2017 Dec 20;6:2153. doi: 10.12688/f1000research.11243.1. PMID: 29333255; PMCID: PMC5749125.
  23. Sipp D, Caulfield T, Kaye J, Barfoot J, Blackburn C, Chan S, De Luca M, Kent A, McCabe C, Munsie M, Sleeboom-Faulkner M, Sugarman J, van Zimmeren E, Zarzeczny A, Rasko JEJ. Marketing of unproven stem cell-based interventions: A call to action. Sci Transl Med. 2017 Jul 5;9(397):eaag0426. doi: 10.1126/scitranslmed.aag0426. PMID: 28679655.
  24. Declerck P, Farouk-Rezk M, Rudd PM. Biosimilarity Versus Manufacturing Change: Two Distinct Concepts. Pharm Res. 2016 Feb;33(2):261-8. doi: 10.1007/s11095-015-1790-3. Epub 2015 Sep 17. PMID: 26381277.
  25. Epstein MS, Ehrenpreis ED, Kulkarni PM; FDA-Related Matters Committee of the American College of Gastroenterology. Biosimilars: the need, the challenge, the future: the FDA perspective. Am J Gastroenterol. 2014 Dec;109(12):1856-9. doi: 10.1038/ajg.2014.151. Epub 2014 Jun 24. PMID: 24957160.
  26. Dougherty MK, Zineh I, Christl L. Perspectives on the Current State of the Biosimilar Regulatory Pathway in the United States. Clin Pharmacol Ther. 2018 Jan;103(1):36-38. doi: 10.1002/cpt.909. Epub 2017 Nov 20. PMID: 29152721.
  27. Peterson J, Budlong H, Affeldt T, Skiermont K, Kyllo G, Heaton A. Biosimilar Products in the Modern U.S. Health Care and Regulatory Landscape. J Manag Care Spec Pharm. 2017 Dec;23(12):1255-1259. doi: 10.18553/jmcp.2017.23.12.1255. PMID: 29172981; PMCID: PMC10398052.

Figures:

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More

Help ?